25th Oct 2016 07:07
LONDON (Alliance News) - Beximco Pharmaceuticals Ltd on Tuesday said the US Food & Drug Administration has approved the firm's Sotalol Hydrochloride product, a generic version of the cardiovascular drug Betapace.
The approval will let Beximco, a Bangladesh-based generic drugs and active pharmaceutical ingredients firm, produce Sotalol tablets in two different strengths. It expects to launch the product in the first quarter of 2017.
"We are delighted to have received our second product approval from the US FDA. Sotalol was fully developed in-house and this approval demonstrates our continued focus on strengthening capabilities, especially our competitive R&D and regulatory skills," said Beximco Managing Director Nazmul Hassan.
Shares in Beximco were up 5.4% to 47.95 pence early Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Beximco Pharma